UK markets open in 4 hours 54 minutes
  • NIKKEI 225

    26,087.53
    -335.94 (-1.27%)
     
  • HANG SENG

    21,738.43
    -114.64 (-0.52%)
     
  • CRUDE OIL

    100.17
    +0.67 (+0.67%)
     
  • GOLD FUTURES

    1,768.20
    +4.30 (+0.24%)
     
  • DOW

    30,967.82
    -129.44 (-0.42%)
     
  • BTC-GBP

    16,625.41
    -406.98 (-2.39%)
     
  • CMC Crypto 200

    430.47
    -9.56 (-2.17%)
     
  • ^IXIC

    11,322.24
    +194.39 (+1.75%)
     
  • ^FTAS

    3,863.91
    -103.70 (-2.61%)
     

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Small Pharma Inc.
Small Pharma Inc.

LONDON, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in a fireside chat at the H. C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond, taking place in-person and virtually.

Format: Fireside Chat (virtual)
Date: June 27, 2022
Time: On-demand from 7:00AM ET
Webcast: Register here

To schedule a one-on-one meeting with Small Pharma’s management team, please contact your assigned HCW representative, or smallpharmair@kcsa.com.

About Small Pharma

Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelics with therapy for the treatment of mental health conditions, with a current focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine (“DMT”) assisted psychotherapy in February 2021. This program includes a Phase I/IIa trial on the Company’s lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

About DMT 

DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30 mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the most advanced clinical trial in commercial development for DMT-assisted psychotherapy in Major Depressive Disorder.

For further information contact: 

Small Pharma Inc.
Peter Rands
Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)20 7112 9118

Investor Relations Contacts:
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com
Tel: +1 (646)-889-1200

Kristi Papanikolaw
KCSA Strategic Communications
Email: smallpharmair@kcsa.com
Tel: +1 (917) 497-9287

Media Relations Contacts:
McKenna Miller
KCSA Strategic Communications
Email: smallpharmapr@kcsa.com
Tel: +1 (949) 949-6585

Cautionary Note

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.

The TSX Venture Exchange (the “TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting